What are the signs and symptoms of cytomegalovirus (CMV)-induced vasculitis?

CMV-Induced Vasculitis: Signs and Symptoms

CMV-induced vasculitis presents most commonly with cutaneous manifestations including purpura, livedo reticularis, and skin ulcerations, though the provided evidence focuses predominantly on CMV end-organ disease in immunocompromised patients rather than isolated vasculitis. 1

Clinical Context and Risk Factors

CMV vasculitis occurs almost exclusively in severely immunocompromised patients, particularly those with:

• CD4+ counts <50 cells/µL in HIV/AIDS patients 1
• Patients on immunosuppressive therapy (corticosteroids, chemotherapy)
• Solid organ or hematopoietic stem cell transplant recipients

Cutaneous Vasculitis Manifestations

When CMV causes vasculitis, the following cutaneous signs appear:

• Purpuric rashes - most common cutaneous finding 2
• Livedo reticularis - particularly on extremities 3, 4
• Papules and nodules 4
• Skin ulcerations - chronic, necrotizing 2, 5
• Necrotizing vasculitis of digits (toes/fingers) 3

The pathophysiology involves leukocytoclastic vasculitis of small dermal vessels with CMV-infected endothelial cells showing characteristic intranuclear inclusions, associated with thrombus formation and luminal narrowing 5.

Systemic Manifestations

CMV vasculitis rarely occurs in isolation. Associated systemic findings include:

Constitutional Symptoms

• Persistent fever 3, 6
• Weight loss 1
• Malaise and fatigue 1

Gastrointestinal Involvement

• Abdominal pain 1, 7
• Hemorrhagic enterocolitis with potential perforation 7
• Massive gastrointestinal bleeding 6

Other Organ Systems

• Splenomegaly and splenic infarcts 4, 8
• Arthralgia 4
• Mesenteric venous thrombosis 8

Laboratory Findings

• Thrombocytopenia - may be an early indicator of CMV infection in vasculitis patients 9
• Atypical lymphocytosis 4
• Elevated inflammatory markers (CRP, ESR)
• CMV viremia detectable by PCR or antigenemia assay 1

Critical Diagnostic Pitfall

CMV antigenemia assays and IgM antibodies may be negative early in disease despite active infection 6. Therefore, maintain high clinical suspicion in immunocompromised patients with vasculitic symptoms even with negative initial serologies. Tissue biopsy showing characteristic intranuclear inclusions in endothelial cells remains the gold standard 5.

Association with ANCA-Associated Vasculitis

Recent evidence suggests CMV infection may trigger or coexist with ANCA-associated vasculitis, presenting with:

• Diffuse alveolar hemorrhage 7
• Glomerulonephritis 7
• Positive MPO or PR3-ANCA 7, 9

This creates a diagnostic and therapeutic dilemma requiring careful timing of immunosuppression versus antiviral therapy 7.

Key Clinical Algorithm

In immunocompromised patients presenting with:

1. Purpura/livedo reticularis + fever → Consider CMV vasculitis
2. Thrombocytopenia during immunosuppression → Test for CMV viremia 9
3. Skin ulceration + systemic symptoms → Perform skin biopsy looking for CMV inclusions in endothelial cells
4. Negative initial CMV testing but high suspicion → Repeat testing and consider tissue diagnosis 6